The chimeric multi-domain proteins mediating specific DNA transfer for hepatocellular carcinoma treatment by unknown
Yang et al. Cancer Cell Int  (2016) 16:80 
DOI 10.1186/s12935-016-0351-0
PRIMARY RESEARCH
The chimeric multi-domain 
proteins mediating specific DNA transfer 
for hepatocellular carcinoma treatment
Encheng Yang1, Xiao Li2 and Ningyi Jin2*
Abstract 
Aim: This study was aimed to evaluate the therapeutic efficiency of a non-virus based specific chimeric multi-domain 
DNA transferred with apoptin in human hepatocellular carcinoma (HCC) HepG-2 cells in vitro and in mice H22 cells 
in vivo.
Methods: We firstly constructed the multi-domain recombinant chimeric proteins based on recombinant proteins 
[G (yeast GAL4), NG (none GAL4), TG (GAL4 + Tat protein) and TNG (Tat protein)] and pUAS-Apoptin plasmid, and 
transfected them into human HepG-2 cells. The antitumor effect of this multi-domain recombinant chimeric proteins 
to HCC cells were detected by MTT assay, AO/EB staining, DAPI staining and Annexin V assay. In order to find the path-
way of cell apoptosis, the Caspase (1, 3, 6 and 8) activity was detected. We then constructed the H22 liver cancer mice 
model and analyzed the anti-tumor rate and mice survival rate after treated with G/pUAS-Apoptin NG/pUAS-Apoptin 
TG/pUAS-Apoptin, and TNG/pUAS-Apoptin.
Results: MTT results showed that the Tat protein (TG and TNG) significantly induced cell death in a time depend-
ent manner. AO/EB, DAPI, Annexin V and Caspases assay results indicated that the Caspase 1, 3, 6 and 8 were highly 
expressed in TG/pUAS-Apoptin, and TNG/pUAS-Apoptin treated mouse groups. The antitumor rate and survival rate in 
TG/pUAS-Apoptin, and TNG/pUAS-Apoptin treated mouse groups were higher than in the other groups.
Conclusion: The Tat-apoptin is a potential anti-tumor agent for HCC treatment with remarkable anti-tumor efficacy 
and high safety based on non-virus gene transfer system. The anti-tumor function may be associated with high 
expression of Caspase 1, 3, 6 and 8.
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Background
Hepatocellular carcinoma (HCC) is a slowly develop-
ing malignant tumor that evolves from premalignant 
lesions in a chronically damaged liver [1–3]. HCC is a late 
complication in patients with chronic liver disease, and 
therefore, is often associated with cirrhosis and mortal-
ity [4, 5]. One of the major reasons for the high mortal-
ity in HCC patients is the limited treatment options and 
poor prognosis [6]. Traditional treatments of HCC, such 
as operation, chemotherapy and radiotherapy, bear some 
side effects and limit the dose that can be administered 
[7, 8]. Therefore, developing effective cancer therapeutic 
strategies is of particular importance for patients with 
HCC.
In the past decades, a line of evidences indicate the 
promising potential of gene therapy for HCC treatment [9, 
10]. As a process of gene transfer, gene therapy is largely 
relied on the development of gene delivery vector. Nowa-
days, there are several kinds of gene delivery systems that 
have been explored, such as modified siRNA, viral vectors 
and non-viral vectors [11]. Viral vector has been widely 
used for the high efficiencies of transfection and foreign 
gene expression, but it shows advantages in oncogenic 
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effects, endogenous virus and unexpected immune 
response. Non-viral vector has gained substantial interest 
for the flexibility in design and non-infectivity [12, 13].
GAL4 protein is known as a transcriptional activator that 
can bind to the galactose upstream active sequence (UAS) 
to stimulate the expression of genes involved in galactose 
metabolic pathway [14]. A previous study has proposed 
that GAL4 is a promising vector for non-viral DNA trans-
fection [15]. Viral NLS (nuclear localization sequence) is 
served as a logical addition to non-viral vector delivery sys-
tem. The fusion protein GAL4-NLS has been determined 
to enhance the DNA transfection efficiency to mammalian 
nuclei [16]. The Tat protein is a transcriptional activator 
from human immunodeficiency virus type 1 (HIV-1) and 
shows the ability to translocate through the plasma mem-
brane [17]. In our preliminary study, a novel fusion pro-
tein termed TG has been found to be an efficient carrier of 
DNA plasmid, which contains GAL4 domain as the carrier 
for DNA plasmid and Tat domain for cell internalization 
[18]. However, the application of fusion protein as the plas-
mid carrier in treating HCC cells has not been reported.
Apoptin is a small apoptosis protein that derived from 
chicken anemia virus. Gene therapy experiments have 
proved that apoptin expression may cause tumor regres-
sion and cell apoptosis without any significant side effect 
[19–21]. In this study, the multi-domain recombinant 
chimeric proteins such as G (GAL4), NG (NLS-GAL4), 
TG (Tat-GAL4 protein) and TNG (Tat-NLS-GAL4 pro-
tein), and pUAS-Apoptin plasmid were constructed. 
We attempted to evaluate the inhibitive effect on HCC 




The 17-mer upstream activating sequence (UAS) was 
obtained by tandem synthesis and then cloned into the 
plasmid vector pIRESneo (Invitrogen, USA) at the XhoI 
site to construct the recombinant plasmid pUAS. The 
recombinant plasmid of chimera pUAS-EGFP was con-
structed by double digestion of plasmid vector pMT-
EGFP and pUAS with restriction endonuclease NotI and 
XbaI. Similarly, the recombinant plasmid pUAS-Apoptin 
was constructed and identified by double digestion of 
pMT-Apoptin and pUAS with endonuclease EcoRI and 
EcoRV. The structure of the plasmid used was showed in 
the Additional file 1: Figure S1.
Plasmid chimera and fusion protein transfection 
into human HepG‑2 cells
The human hepatoma HepG-2 cells (Chinese Academy 
of Sciences, China) were routinely cultured at 37  °C in 
5  % CO2. The schematic representation of transfection-
expression strategy was listed in Additional file 2: Figure 
S2.
Before pUAS-EGFP transfection, HepG-2 cells 
(1  ×  105 cell/well) were seeded in a 96-well plate 
and cultured until 80  % confluence. These cells were 
transfected with 10  μl of recombinant pUAS-EGFP 
and 32 μl of fusion protein G, NG, TG and TNG (con-
structed in our previous study [18]) followed by cul-
turing for 48 h at 37 °C under 5 % CO2. The cells were 
then observed by fluorescence microscope (Olympus, 
Japan). The equal volume of normal saline treated 
cells and the plasmid/lipidosome complex cells 
were used as negative control and positive control, 
respectively.
For pUAS-Apoptin transfection, cells were plated at 
5 × 103 cell/well in a 96-well plate, and then transfected 
with 1  μl of pUAS-Apoptin recombinant and 3.2  μl of 
G, NG, TG and TNG, respectively. Subsequently, the 
cells were cultured at 37  °C under 5  % CO2. Cells that 
were cotransfected with liposome and pUAS-EGFP were 
served as positive controls.
MTT assay
The 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium 
chloride (MTT) assay was conducted for evaluating the 
effects of TG/pUAS-Apoptin and TNG/pUAS-Apoptin on 
HepG-2 cell proliferation. In brief, after transfection for 12, 
24, 36, 48, 60, 72, 84 and 96 h, the transfected cells were 
treated with 20 μl MTT (5 mg/ml, Sigma, USA) per well for 
4 h. After that, the liquid supernatant of culture medium 
was discarded, and 150 μl DMSO was added per well to dis-
solve the precipitate. Absorbance was measured at 490 nm 
(A490) with normal saline treated cells as controls. Sup-
pression rate as calculated as follows: suppression rate (%) 
= (1− A490 in treatment group/A490 in control group)× 
100 % .
Apoptosis assay
Apoptosis was evaluated by flow cytometry Annexin V 
Flous staining. In brief, HepG-2 cells were trypsinized 
and washed with phosphate buffer solution (PBS) after 
60  h of transfection. After centrifuged at 3000  rpm/
min for 5 min at 4  °C, 1 × 105 cells, were re-suspended 
in 195 μl of binding buffer, and added with 5 μl of fluo-
rescein isothiocyanate (FITC)-labeled annexin V (Beyo-
time, China) for 10  min. Subsequently, the cells were 
centrifuged and re-suspended in 190 binding buffer fol-
lowed by dyeing with 10 μl of propidium iodide (PI) for 
5  min. Flow cytometry was conducted with the normal 
saline treated cells as controls. The same experiment was 
repeated for three times.
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AO/EB and DAPI (4′, 6‑diamidino‑2‑phenylin‑dole) staining
AO/EB and DAPI staining were conducted for the obser-
vation of cellular morphology. With respect to AO/EB 
staining, transfected cells were firstly washed and re-sus-
pended with PBS, and then stained with 1 μl of acridine 
orange (AO, Sigma, USA) and 1 μl of ethidium bromide 
(EB, Sigma, USA) solution. As to DAPI staining, the trans-
fected HepG-2 cells were washed with PBS and re-sus-
pended with alcohol, followed by 0.5 % Triton treatment 
for cell permeabilization. Then the cells were collected 
and stained with DAPI (Sigma, USA) for 15 min.
After staining, the morphologic changes of cells were 
observed under a fluorescence microscope at 3 random 
fields (≥300 cells/each field). The saline treated cells were 
used as normal controls.
Detection of protein concentration and caspase activity
Protein concentrations were detected by 2,2′-biquino-
line-4,4-dicarboxylic acid disodium salt (BCA, Beyotime, 
China) assay. Briefly, the transfected cells were firstly 
washed with PBS and treated with lysis buffer for 15 min 
in ice-water. For protein preparation, the cells were 
centrifuged at 4  °C for 15 min and the supernatant was 
collected for the following investigation. The working 
reagent was prepared by BCA Protein Assay Kit accord-
ing to the manufacturers’ instruction. The standard 
sample was fully dissolved and diluted to a final concen-
tration of 0.5 mg/ml with PBS. A serial volume of stand-
ard samples (0, 1, 2, 4, 8, 12, 16 and 20 μl), and 20 μl of 
protein sample were respectively added into the enzyme-
linked immunosorbent assay (ELISA) plate. The mixture 
was supplemented with PBS to 20  μl, and reacted with 
200 μl of working reagent. Based on the standard curve, 
absorbance was measured at 562  nm (A562) for protein 
concentrations calculation.
The enzymatic activity of caspase 1, 3, 6 and 8 was 
detected with the similar method described above, while 
the reaction was initiated after adding 2  mM of Ac-
YVAD-pNA at 37  °C for 120  min and absorbance was 
observed at 405 nm.
Construction of H22 HCC mouse model (C57BL/6)
The 6-week old female C57BL/6 mice were purchased 
from the People’s Liberation Army Academy of Mili-
tary Medical Sciences, China. The animal experiments 
were approved by the Institutional Animal Care and Use 
Committees and the study procedures were performed 
in accordance with the guidelines of the National Insti-
tutes of Health Guide for the Care and Use of Laboratory 
Animals. Mice were fed with standard rodent chow and 
raised under room temperature.
The H22 HCC mouse model was constructed as fol-
lows: the mice were firstly intraperitoneally inoculated 
with H22 cells (obtained from laboratory animal center 
of Jilin University, China). After 7–10  days incuba-
tion, ascites was extracted. H22 cells (1  ×  107 cell/ml) 
in ascites were washed for three times, and subcutane-
ously injected into the right hind leg of the mice (100 μl, 
1 × 106 cells). The model was considered to be success-
fully constructed when the tumor nodules grew in a 
diameter of 3–5 mm.
Grouping and treatment
A total of 54 HCC model mice were randomly divided 
into nine groups (n  =  6 per group), including the nor-
mal saline, pUAS, pUAS-Apoptin, TG, TNG, TG/pUAS, 
TG/pUAS-Apoptin, TNG/pUAS and TNG/pUAS-Apop-
tin treatment group. Additional six normal mice were 
enrolled in the control group.
Total 100  μg of corresponding plasmid or fusion pro-
tein or combined plasmid and fusion protein (at dos-
age ratio 1:32) was injected to mice for three times with 
10-day interval, which was prior dissolved in 100  μl of 
saline. Mice in the normal saline treatment group were 
treated with 100  μl of normal saline solution. All the 
treated mice were sacrificed at 16  days after the final 
treatment.
Detection for survival rate and tumor volume
After treatment, the tumor diameter (D) and thickness 
(T) were measured by vernier caliper every 2  days. The 
tumor volume (V) =  D ×  T2 ×  0.52. Anti− tumor rate 
= (Vnormal saline−Vtreatment group)/Vnormal saline × 100 %  . 
Simultaneously, survival rate was calculated for each group 
and Kaplan–Meier curve was used for survival analysis.
Tissue section analysis
The tumor tissues extracted from mice were fixed in 10 % 
formalin for 24–72 h, and dehydrated with ethyl alcohol 
and xylene. Then the tissues were embedded in paraffin 
and cut into 4-μm-thick sections. The slides were stained 
with hematoxylin-eosin (HE), and observed by using an 
light microscope at 40× magnification.
Statistical analysis
All data were presented as mean  ±  standard deviation 
(SD). Comparison between groups was performed with 
the t test. Kaplan–Meier curve was conducted for sur-




The recombinant plasmid pUAS, pUAS-EGFP and 
pUAS-Apoptin were identified by double digestion with 
corresponding restriction endonucleases. Finally, DNA 
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fragments with length of approximately 100, 750 and 
360  bp were obtained after double digestion of pUAS, 
pMT-EGFP and pMT-Apoptin, respectively, which deter-
mined that the recombinant plasmid of pUAS, pMT-
EGFP and pMT-Apoptin were constructed successfully.
Transfection of fusion proteins and recombinant plasmids 
into HepG‑2 cells
Green fluorescence was only observed in HepG-2 cells 
transfected with TG/pUAS-EGFP and TNG/pUAS-EGFP 
for 48 h, as well as with the liposome/pUAS-EGFP. There 
was no green fluorescence in HepG-2 cells transfected with 
other fusion proteins and/or recombinant plasmids (Fig. 1).
Cytotoxicity of pUAS‑Apoptin to HepG‑2 cells
The cytotoxicity of pUAS-Apoptin and fusion proteins to 
HepG-2 cells was detected by MTT staining (Fig.  2). At 
12 h (Fig. 2a) and 24 h (Fig. 2b), the suppression rates of 
HepG-2 cells transfected with TG/pUAS-Apoptin, TNG/
pUAS-Apoptin or lipidosome/pUAS-Apoptin showed no 
significant difference when compared with that of HepG-2 
cells transfected with G/pUAS-Apoptin and NG/pUAS-
Apoptin (P > 0.05). However, at 36 h of incubation (Fig. 2c), 
the suppression rates were significantly higher in HepG-2 
cells transfected with TG/pUAS-Apoptin, TNG/pUAS-
Apoptin and lipidosome/pUAS-Apoptin than those trans-
fected with G/pUAS-Apoptin and NG/pUAS-Apoptin 
(P < 0.05), indicating that the TG, TNG and lipidosome sig-
nificantly mediated pUAS-Apoptin cytotoxicity to HepG-2 
cells (the rest graphs for treatment at 48 h (D), 60 h (E), 72 h 
(F), 84 h (G), and 96 h (H) were showed in the Additional 
file 3: Figure S3). In addition, HepG-2 cells transfected with 
lipidosome/pUAS-Apoptin showed higher suppression rate 
than those transfected with TG/pUAS-Apoptin and TNG/
pUAS-Apoptin at 12, 24 and 36 h of incubation (P < 0.05). 
The cytotoxic effect of pUAS-Apoptin induced by TG and 
TNG reached the peak at 48–60 h of incubation.
pUAS‑Apoptin induced cell apoptosis mediated by TG 
and TNG
After treated with FITC-labeled annexin V and PI, 
HepG-2 cells were tested by flow cytometer for cell apop-
tosis. The apoptosis rates were 22.58 and 19.73  % for 
HepG-2 cells transfected with TG/pUAS-Apoptin and 
TNG/pUAS-Apoptin, respectively, which showed no sig-
nificant difference with that of HepG-2 cells transfected 
with lipidosome (24.91 %) (Fig. 3).
pUAS‑Apoptin induced changes in cellular morphology 
mediated by TG and TNG
Changes in cellular morphology was observed by AO/
EB staining and DAPI staining. The AO/EB staining 
showed that TG/pUAS-Apoptin, TNG/pUAS-Apoptin 
and lipidosome/pUAS-Apoptin transfected cells exhib-
ited a red color in the nucleus, indicating that these cells 
were dead and the membrane integrity was destroyed 
(Fig.  4h–j). Conversely, the G/pUAS-Apoptin and NG/
pUAS-Apoptin transfected cells showed a green color 
in the core (Fig.  4a–g), indicating that these cells were 
alive. By staining with DAPI, the visualized nucleus was 
broken and disintegrated in TG/pUAS-Apoptin, TNG/
pUAS-Apoptin and liposome/pUAS-Apoptin trans-
fected cells, while the cell nuclei were integrated in the 
other groups.
The rates of cell death in TG/pUAS-Apoptin, TNG/
pUAS-Apoptin and liposome/pUAS-Apoptin groups were 
77.67, 72.67 and 64 %, respectively based on AO/EB stain-
ing (Table 1), while the apoptotic rates were 45.00, 36.00 and 
61.33 % by DAPI staining (Fig. 5; Table 1). The cell apoptotic 
rates were significantly higher in TG/pUAS-Apoptin, TNG/
pUAS-Apoptin and liposome/pUAS-Apoptin group than 
those in G/pUAS-Apoptin and NG/pUAS-Apoptin group 
(P < 0.05). These results indicated that pUAS-Apoptin could 
induce cellular morphology changes induced by cell death, 
when mediated by TG and TNG.
TG and TNG mediated pUAS‑Apoptin induced caspase 
activity
To detect whether the caspase involved in the cell apop-
tosis of HepG-2 cells in different groups, the activity of 
caspase was detected. Figure 6 showed that the activity of 
Caspase 1, 3, 6 and 8 was significantly increased in TG/
pUAS-Apoptin, TNG/pUAS-Apoptin and lipidosome/
pUAS-Apoptin group.
TG and TNG mediated pUAS‑Apoptin inhibited tumor 
growth in H22 induced HCC mice
Tumor volume of mice in different treatment groups 
were recorded during treatment. As a result, the tumor 
volume was smaller in TG/pUAS-Apoptin and TNG/
pUAS-Apoptin treated mice group than in the other 
groups at the same time point (Additional file  4: Table 
S1). Besides, the tumor suppression rates in TG/pUAS-
Apoptin and TNG/pUAS-Apoptin groups were 27.02 
and 28.59 %, respectively, which were higher than other 
groups (Fig. 7).
pUAS‑Apoptin elevated survival rate of HCC model mice 
when mediated by TG and TNG
Survival curve showed that the mean survival rates of 
HCC model mice treated by TG/pUAS-Apoptin (66.7 %) 
and TNG/pUAS-Apoptin (66.7 %) were relatively higher 
than those in the other treatment groups such as normal 
saline (33.3 %), pUAS (33.3 %), pUAS-Apoptin (50 %), TG 
(16.7  %), TNG (33.3  %), TG/pUAS (16.7  %) and TNG/
pUAS (33.3 %) (Fig. 8).
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pUAS‑Apoptin induced cell death in HCC model mice 
when mediated by TG and TNG
HE staining results showed that the tumor cells obtained 
from mice treated by saline, pUA, TG, TNG, TG/pUAS 
and TNG/pUAS were normal and vigorous. The tumor 
tissue treated with TG/pUAS-Apoptin and TNG/pUAS-
Apoptin and pUAS-Apoptin showed increased intercel-
lular space, cell shrinkage and thick dyeing (Fig. 9).
Discussion
In the present study, we designed several novel non-viral 
gene delivery vehicles (G, NG, TG, TNG) for pUAS-
Apoptin plasmid transfection, and evaluated their com-
bined therapeutic effect on human HCC in  vitro and 
in  vivo. As a result, the TG/pUAS-Apoptin and TNG/
pUAS-Apoptin showed high therapeutic effect on 
promoting cell apoptosis by mediating the activity of 
Fig. 1 The transfection of the recombinant fused protein in HepG-2 cells observed by fluorescence microscope at ×40 magnification. Green  
fluorescence was only found in HepG-2 cells transfected with TG/pUAS-EGFP and TNG/pUAS-EGFP for 48 h, as well as with the liposome/pUAS-EGFP. 
a TG/pUAS-EGFP; b TNG/pUAS-EGFP; c G/pUAS-EGFP; d NG/pUAS-EGFP; e liposome/pUAS-EGFP; f HepG-2 cell
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Caspase 1, 3, 6 and 8 and reducing mortality of model 
mice.
After HepG-2 cells were transfected with pUAS-EGFP 
mediated by G, NG, TG and TNG, green fluorescence 
was only observed in HepG-2 cells transfected with TG/
pUAS-EGFP and TNG/pUAS-EGFP for 48 h, as well as 
with the liposome/pUAS-EGFP, which suggested the 
pUAS-EGFP plasmid were transfered to cells effectively 
by TG and TNG delivery vehicles. In addition, the sup-
pression rates of HCC cells were significantly higher in 
HepG-2 cells transfected with TG/pUAS-Apoptin, TNG/
pUAS-Apoptin and lipidosome/pUAS-Apoptin than oth-
ers and the cytotoxic effect of pUAS-Apoptin induced by 
TG and TNG was in a time dependent manner. All these 
Fig. 2 MTT assay for the suppression rate of various treatment to HepG-2 cells after 12 h (a), 24 h (b) and 36 h (c). From the 36 h of incubation, the 
suppression rates were significantly higher in HepG-2 cells transfected with TG/pUAS-Apoptin, TNG/pUAS-Apoptin and lipidosome/pUAS-Apoptin 
than that of HepG-2 cells transfected with G/pUAS-Apoptin and NG/pUAS-Apoptin (P < 0.05). Asterisk indicates significant difference compared with 
G/pUAS-Apoptin, NG/pUAS-Apoptin, G, NG, TG and TNG treated cells at P = 0.05 level. Hash indicates significant difference between the liposome/
pUAS-Apoptin with TG/pUAS-Apoptin and TNG/pUAS-Apoptin
Fig. 3 Cell apoptosis detected by Annexin V assay
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suggested that the TG and TNG were the effective deliv-
ery system for bare plasmids, and the apoptosis rate of 
HepG-2 cells transfected with pUAS-Apoptin by TG and 
TNG was comparable to liposome delivery vehicle. As a 
small apoptosis-inducing protein, apoptin has attracted 
great interest because it can specifically kill tumor cells 
and leave the normal cells unharmed [22, 23]. Apoptin 
is found to be located in the cytoplasm of normal cells 
while mainly in nucleus of cancer cells [24]. This location 
is suggested to be the major mechanism of anti-tumor 
cell killing mediated by apoptin. Previous studies have 
demonstrated the selective anti-tumor activity of apop-
tin in several human tumor cells, such as melanoma, 
lymphoma, hematoma, colon carcinoma, and breast 
[25, 26]. In tumor cell selectivity, apoptin is able to trig-
ger the Caspases independently, and this process is also 
proved to be independent of death receptors [27, 28]. 
High levels of apoptin in transformed cells activate the 
release of cytochrome c and Caspase 3 and -7 and result 
in a serious cell apoptosis which is not only involved with 
Bcl-2, caspase dependent pathways but also involved 
with the APAF-1 apoptosome-mediated mitochondrial 
death pathway [29, 30]. In addition, the apoptin induced 
cell death is intensively influenced by the regulators in 
mitochondrial pathway [29]. A study showed that when 
recombined into the JDK plasmid, apoptin gene could 
Fig. 4 AO/EB staining result of different treated HepG-2 cells (×40). TG/pUAS-Apoptin, TNG/pUAS-Apoptin and lipidosome/pUAS-Apoptin trans-
fected cells exhibited a red color in the nucleus, indicating that these cells had lost membrane integrity and dead. Conversely, the G/pUAS-Apoptin 
and NG/pUAS-Apoptin transfected cells showed a green color in the core, indicating that these cells were alive. a G; b NG; c TG; d TNG; e liposome;  
f G/pUAS-Apoptin; g NG/pUAS-Apoptin; h TG/pUAS-Apoptin; i TNG/pUAS-Apoptin; j liposome/pUAS-Apoptin
Table 1 The counts of  apoptosis cells stained by  AO/EB 
and DAPI staining
a Indicates significant difference compared with G, NG, TG, TNG, liposome, G/




Dead cell  
percentage (%)
N = 300
AO/EB DAPI AO/EB DAPI
G 17 26 5.67 8.67
NG 43 27 14.33 9.00
TG 28 14 9.33 4.67
TNG 37 31 12.33 10.33
Liposome 21 9 7.00 3.00
G/pUAS-Apoptin 36 12 12.00 4.00
NG/pUAS-Apoptin 51 25 17.00 8.33
TG/pUAS-Apoptin 233a 135a 77.67a 45.00
TNG/pUAS-Apoptin 218a 108a 72.67a 36.00
Liposome/pUAS-Apoptin 192a 184a 64.00a 61.33
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significantly reduce the tumor volume to 16 % of the con-
trol PBS-treated tumors in  vivo [31]. The present study 
indicates that the activity of Caspase 1, 3, 6 and 8 was all 
significantly induced in TG/pUAS-Apoptin, TNG/pUAS-
Apoptin and lipidosome/pUAS-Apoptin group. Besides, 
the tumor volume was smaller in TG/pUAS-Apoptin 
and TNG/pUAS-Apoptin treated mice group. When 
mediated by TG and TNG, pUAS-Apoptin significantly 
suppressed the tumor with anti-tumor rate of 27.02 and 
28.59 % respectively.
Tat protein encoded by HIV-1 is a regulatory protein 
that promotes viral transcription and replication [32]. 
The capacity of Tat to enter cytosol has been used for 
protein imported to cells [33–35]. A minimum effec-
tive sequence, named Tat basic domain, is able to target 
attached proteins into the nucleus [17]. It was reported 
that when the basic domain was deleted or mutated, Tat 
was unable to be delivered to the nucleus [36, 37]. When 
attached to beta-galactosidase, the basic domain chimera 
is more efficiently to target to the nucleus [38]. Previous 
study has proved that the Tat-apoptin could migrate from 
the cytoplasm to the nucleus in Saos-2 and HSC-3 cells 
and then led to cell apoptosis [39]. In one of our previous 
studies, a combination of GAL4/147 with Tat (named as 
TG) has been constructed, which has been demonstrated 
as the efficient non-viral DNA transfer vectors for fur-
ther improvements of gene therapy strategies [18]. These 
results were supported by the present results that TG and 
TNG protein successfully delivered pUAS-Apoptin plas-
mid into HCC cells in vitro and in vivo.
A novel gene transfer strategy is developed for the 
effective delivery system and the clinical practice [40, 
41]. In spite of the effective mediation of Tat on gene 
transfer, the exogenous gene carried apoptin was also 
successfully expressed by regulating HCC cell death 
[42]. MTT assay in our study suggests that the TG and 
TNG mediated pUAS-Apoptin significantly induced 
cancer cell death in a time dependent manner. We then 
detected the cell death pathway by Annexin V assay, 
AO/EB and DAPI staining and Caspase activity, and 
found that the pUAS-Apoptin transfection mediated 
by TG and TNG in HepG-2 cells significantly induced 
cell apoptosis by increasing the activity of Caspase 1, 
3, 6 and 8. The anti-tumor efficiency was also proved 
by the animal experiment on H22 induced liver cancer 
mice model. The mice in TG/pUAS-Apoptin and TNG/
pUAS-Apoptin treated groups had a relatively higher 
anti-tumor rate and survival rate than that in the other 
Fig. 5 DAPI staining result of different treated HepG-2 cells (×100). The visualized nucleus was broken and disintegrated in TG/pUAS-Apoptin, TNG/
pUAS-Apoptin and liposome/pUAS-Apoptin transfected groups, while they were integrated in the other groups. a G; b NG; c TG; d TNG; e liposome; 
f G/pUAS-Apoptin; g NG/pUAS-Apoptin; h TG/pUAS-Apoptin; i TNG/pUAS-Apoptin; j liposome/pUAS-Apoptin
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Fig. 6 Caspase assay in different treated HepG-2 cells. The activity of Caspase 1, 3, 6 and 8 was significantly induced in TG/pUAS-Apoptin, TNG/
pUAS-Apoptin and lipidosome/pUAS-Apoptin group. a Caspase 1; b Caspase 3; c Caspase 6; d Caspase 8. Asterisk indicates significant difference 
compared with G/pUAS-Apoptin, NG/pUAS-Apoptin, G, NG, TG and TNG treated cells at P = 0.05 level
Fig. 7 The tumor suppression rates in H22 induced HCC mice after pUAS-Apoptin plasmid transfection with different gene delivery vehicles
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Fig. 8 Kaplan–Meier curve for analysis of survival rate of different treated HepG-2 cells
Fig. 9 The pathological section assay stained by HE (×40). a saline; b pUAS; c TG; d TNG; e TG/pUAS; f TNG/pUAS; g pUAS-Apoptin; h TG/pUAS-
Apoptin; i TNG/pUAS-Apoptin
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groups, indicating TG and TNG were the effective deliv-
ery of pUAS-Apoptin plasmid in vivo. Based on a virus 
delivery of lentivirus (LV), Ma et  al. [43] investigated 
the antitumor efficacy of secretory Tat-apoptin for HCC 
cells and found that most of the HCC xenograft tumors 
disappeared following the treatment of LV-secretory 
signal peptide (SP)-Tat-apoptin/GFP. Although the ani-
mal study has demonstrated a low toxicity of SP-Tat-
apoptin in vivo, it may have potential toxicity in widely 
clinical application. Herein, with a design of a non-virus 
gene delivery based on Tat-apoptin system, our study 
may provide a safer and effective gene therapeutic strat-
egy in vitro and in vivo.
Although the synthetic protein delivery carriers show 
advantages in flexibility in design and non-infectivity, 
whether TG and TNG affects the specificity of apoptosis 
induction in cancer cells vs. normal cells should be fur-
ther validated. In addition, whether the non-viral delivery 
carrier improves the Apoptin expression should be fur-
ther investigated.
In conclusion, we construct a chimeric multi-domain 
protein mediated specific DNA transfer, and apply it on 
HCC treatment in vitro and in vivo. The results strongly 
demonstrate that the systemic delivery of non-virus 
based Tat-apoptin is feasible in liver cancer treatment. 
Rigorous study is still needed for further verification of 
our results and fully understanding of corresponding 
mechanisms.
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